Gelonghui, April 3 | Enhua Pharmaceutical (002262.SZ) bucked the trend and increased by more than 7%. It now reports 23 yuan, with a market value of 23.1 billion yuan. According to news, the company's revenue in '23 was 5,042 billion yuan, up 17.28% year on year; net profit to mother was 1,037 billion yuan, up 15.12% year on year. CICC commented that the company's performance was in line with expectations, focusing on the volume of major core products. Maintain an outperforming industry rating and maintain a target price of 30 yuan.
A股异动 | 业绩符预期，恩华药业涨超7%
Changes in A-shares | Performance is in line with expectations, Enhua Pharmaceutical rose more than 7%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.